Audeotherapy.com
Audeotherapy.com

Сomplains Policy

Complaints Policy

Terms of Sale

All products offered for sale by AudeoTherapy are subject to availability. We reserve the right to impose quantity limits on any order or reject all or part of an order without prior notice. If an error occurs, we may correct it, revise your order (including adjusting the price), or cancel the order and refund any amounts charged. Product prices are subject to change at any time. You are responsible for any applicable taxes, duties, customs fees, or other governmental levies (“Taxes”) related to your purchase. AudeoTherapy will collect applicable Taxes when required and will provide an estimate at checkout unless otherwise noted. Actual Taxes charged may differ due to factors like system calculations or tax rate changes. In some jurisdictions, you may be required to report and pay taxes directly if we do not collect them.

Only accepted payment methods may be used to complete purchases through our platform. By submitting payment information, you confirm authorization to use your designated payment method. You authorize us to charge the total amount of your order, including applicable taxes, shipping, and handling fees. If a payment method is declined, we will attempt to process the transaction until it is successful. AudeoTherapy and its third-party payment processors may receive updated payment details from your card issuer (e.g., updated numbers or expiration dates) and may use such information for future transactions unless you opt out with your card issuer. We are not responsible for fees imposed by your bank or card issuer.

If any items in your order are unavailable, charges will apply only to the shipped items, including applicable Taxes and fees. You may be asked to provide transaction-related information such as billing and shipping addresses, contact details, and payment card information. By submitting this information, you grant AudeoTherapy and its third-party partners the right to use it to process and facilitate the transaction.

All transactions occur through our third-party payment processor. For details about their policies, including privacy and security measures, please refer to their website. AudeoTherapy’s relationship with these vendors is strictly contractual and does not imply agency, partnership, or other fiduciary relationships.

Shipping and handling charges are displayed at checkout. We reserve the right to change these charges at any time, with notice provided before purchase. Estimated delivery times are not guaranteed, and the risk of loss passes to the buyer upon transfer to the carrier unless stated otherwise.

We handle user concerns on a case-by-case basis and reserve the right to resolve issues at our sole discretion, considering the specific circumstances.

Termination

AudeoTherapy reserves the right to terminate your access to the platform, features, or services at any time without prior notice. This may occur due to violations of the Terms, termination of agreements with third-party providers, or service discontinuation. Provisions regarding security, liability, intellectual property, and dispute resolution shall survive termination.

If your access is terminated, you may not attempt to re-access the platform under any name or account. Violations of this restriction may result in liability for damages to AudeoTherapy.

Except as required by law or stated in our Privacy Policy, we have no obligation to return or provide access to any information you submitted to us after termination.

Refunds

Orders must be canceled before processing begins. Subscription cancellations must occur at least seven days before renewal. Refunds are not available for orders already being processed.

Scroll to Top

Safety Information

Critical Details About Compounded Semaglutide

Compounded medications are legally allowed to be prescribed under federal law; however, they are not FDA-approved and do not undergo FDA evaluation for safety, efficacy, or production standards. At AudeoTherapy, compounded semaglutide is prescribed based on an individualized medical assessment.

WARNING: Potential Risk of Thyroid C-Cell Tumors
Research in animals has linked semaglutide, the active ingredient in some GLP-1 receptor agonists, to thyroid tumors, including medullary thyroid carcinoma (MTC). It is unclear if semaglutide causes similar tumors in humans. Notify your healthcare provider immediately if you notice symptoms of thyroid cancer, such as neck lumps or swelling, hoarseness, swallowing difficulties, or shortness of breath. Compounded semaglutide is not suitable for individuals with personal or family histories of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Uses of Compounded Semaglutide
Compounded semaglutide is intended for use alongside a reduced-calorie diet and increased physical activity to manage chronic weight in adults who meet the following criteria:

  • A body mass index (BMI) of 30 kg/m² or higher (classified as obesity), or
  • A BMI of 27 kg/m² or higher (overweight) with at least one weight-related condition, such as type 2 diabetes, hypertension, or abnormal cholesterol levels.

Usage Restrictions

  • Do not use compounded semaglutide in combination with other GLP-1 receptor agonists or semaglutide-containing products.
  • Its safety and effectiveness when combined with other weight management medications have not been established.
  • Patients with a history of pancreatitis or gastroparesis have not been studied for this treatment.

Avoid Use If You:

  • Have a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.
  • Are diagnosed with type 1 diabetes, pancreatitis, or gastroparesis.
  • Are allergic to semaglutide or any inactive ingredients.
  • Have a history of suicidal thoughts or behavior.

Precautions and Warnings:

  • Acute Pancreatitis: Stop using the medication if pancreatitis is suspected.
  • Gallbladder Issues: Monitor for symptoms of gallbladder disease, including gallstones, and seek medical advice as needed.
  • Low Blood Sugar: When combined with insulin or similar medications, there is an increased risk of hypoglycemia. Regularly monitor blood sugar and adjust doses as recommended by your provider.
  • Kidney Health: Monitor kidney function, particularly in patients with renal impairment or those experiencing severe gastrointestinal effects.
  • Mental Health Concerns: Watch for mood changes, depression, or suicidal thoughts, and discontinue use if these symptoms occur.

Pregnancy and Fertility Considerations
Semaglutide may harm an unborn child. Avoid use during pregnancy or if planning to become pregnant. Stop treatment at least two months before attempting to conceive.

Common Side Effects:
Frequently reported side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, fatigue, headaches, and low blood sugar in patients with type 2 diabetes.

Potential Drug Interactions:
Compounded semaglutide slows gastric emptying, which could impact the absorption of oral medications. Consult your healthcare provider to manage potential interactions effectively.

Medication Disclaimer

Essential Information on Medications: Saxenda®, Victoza®, Wegovy®, and Ozempic® are patented products of Novo Nordisk™, while Eli Lilly and Company™ produce Mounjaro™ and Zepbound. This website is not affiliated with, endorsed by, or connected to these companies or their products in any capacity. While these FDA-approved medications may be available through other sources, we do not provide them, and they are currently experiencing supply shortages. During such shortages, pharmacies might prepare compounded versions of these drugs, provided they comply with the Federal Food, Drug, and Cosmetic Act’s requirements. Compounded medications are valuable for patients with unique medical needs that FDA-approved drugs cannot address. However, it is important to note that compounded drugs are not FDA-approved, nor do they undergo premarketing evaluations for safety, effectiveness, or quality. The FDA has not assessed these medications for their intended uses, nor has the manufacturing process for compounded drugs been reviewed by the FDA.